Page 401 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 401
Sanofi (Beijing) Pharmaceuticals Co., Ltd 440 E
Sequana Medical AG 300 A
1, Technoparkstrasse
8005 Zurich
Switzerland
www.sequanamedical.com
Sequana Medical is a Swiss medical device company dedicated to improving patient
lives through innovative technologies to manage fluid balance within the body. Sequana
Medical's alfapump® (automated low-flow ascites) system is a fully implantable battery-
powered pump system for the management of ascites. The alfapump system automatically
and continually moves ascites as it forms to the bladder, significantly reducing the need
for large volume paracentesis and improving patient quality of life. Sequana Medical has
recently launched its next generation product, alfapump with DirectLink Technology, which
allows clinicians to monitor the alfapump remotely.
Shire Pharmaceuticals 240 J
Zählerweg 10
6300 Zug
Switzerland
www.shire.com
Shire is one of the world’s leading specialty biopharmaceutical companies - but, more INDUSTRY INFORMATION
importantly, we make a difference to people with life-altering conditions, enabling them
to lead better lives. Shire’s vision is to continue to identify, develop and supply life-
changing products that support physicians in transforming the lives of patients with
specialist conditions. Fostering innovation and delivering value not only promises a better
understanding of diseases but also provides the best hope of treating and eventually
eliminating them. Shire aims to be at the forefront of the development and provision of
treatments for GI diseases including ulcerative colitis , chronic constipation, cholestatic liver
disease, and non-alcoholic steatohepatitis.
Sirtex Medical Europe GmbH 420 A
33, Joseph-Schumpeter-Allee
Bonn, 53227
Germany
www.sirtex.com
Sirtex Medical is actively engaged in the field of liver-directed therapies for cancer patients.
Our innovative technology, SIR-Spheres® microspheres (Yttrium-90 resin beads), was
approved in 2002 for use in the treatment of a variety of unresectable liver tumours a well
as in hepatocellular carcinoma within the European Union under a CE Mark. SIR-Spheres®
microspheres are presently used at 250+ institutions in Europe. Data from SIRFLOX, a
randomised controlled study evaluating SIR-SpheresY-90 resin microspheres in combination
with a current chemotherapy regimen for the first-line treatment of unresectable colorectal
liver metastases, are expected later in 2015.
Vienna, Austria • April 22–26, 2015 401
Sequana Medical AG 300 A
1, Technoparkstrasse
8005 Zurich
Switzerland
www.sequanamedical.com
Sequana Medical is a Swiss medical device company dedicated to improving patient
lives through innovative technologies to manage fluid balance within the body. Sequana
Medical's alfapump® (automated low-flow ascites) system is a fully implantable battery-
powered pump system for the management of ascites. The alfapump system automatically
and continually moves ascites as it forms to the bladder, significantly reducing the need
for large volume paracentesis and improving patient quality of life. Sequana Medical has
recently launched its next generation product, alfapump with DirectLink Technology, which
allows clinicians to monitor the alfapump remotely.
Shire Pharmaceuticals 240 J
Zählerweg 10
6300 Zug
Switzerland
www.shire.com
Shire is one of the world’s leading specialty biopharmaceutical companies - but, more INDUSTRY INFORMATION
importantly, we make a difference to people with life-altering conditions, enabling them
to lead better lives. Shire’s vision is to continue to identify, develop and supply life-
changing products that support physicians in transforming the lives of patients with
specialist conditions. Fostering innovation and delivering value not only promises a better
understanding of diseases but also provides the best hope of treating and eventually
eliminating them. Shire aims to be at the forefront of the development and provision of
treatments for GI diseases including ulcerative colitis , chronic constipation, cholestatic liver
disease, and non-alcoholic steatohepatitis.
Sirtex Medical Europe GmbH 420 A
33, Joseph-Schumpeter-Allee
Bonn, 53227
Germany
www.sirtex.com
Sirtex Medical is actively engaged in the field of liver-directed therapies for cancer patients.
Our innovative technology, SIR-Spheres® microspheres (Yttrium-90 resin beads), was
approved in 2002 for use in the treatment of a variety of unresectable liver tumours a well
as in hepatocellular carcinoma within the European Union under a CE Mark. SIR-Spheres®
microspheres are presently used at 250+ institutions in Europe. Data from SIRFLOX, a
randomised controlled study evaluating SIR-SpheresY-90 resin microspheres in combination
with a current chemotherapy regimen for the first-line treatment of unresectable colorectal
liver metastases, are expected later in 2015.
Vienna, Austria • April 22–26, 2015 401
